Scholarlink

Background <p>To evaluate fertility, weight loss, improvement in obesity related comorbidities, and pregnancy outcomes over five years following metabolic bariatric surgery (laparoscopic sleeve gastrectomy [LSG] and laparoscopic Roux-en-Y gastric bypass [LRYGB]) in morbidly obese premenopausal women with infertility or planning pregnancy.</p> Methods <p>This retrospective cohort study included 79 adult females with morbid obesity who underwent LSG (<i>n</i> = 38) or LRYGB (<i>n</i> = 41). After 5 years of follow up: we evaluated percentage excess weight loss (%EWL), comorbidities improvement, postoperative complications or mortality, and fertility outcomes. Fertility outcomes were assessed in three subgroups: primary infertility (<i>n </i>= 21), secondary infertility (<i>n</i> = 8), and pre-marriage patients (<i>n</i> = 50).</p> Results <p>Both procedures achieved sustained weight loss (5-year %EWL: LSG 63.1 ± 1.5%, LRYGB 65.2 ± 8.1%; p = 0.16). Conception rates were high across all subgroups (primary infertility: LSG 80%, LRYGB 72.7%; secondary infertility: 100% both; pre-marriage: LSG 100%, LRYGB 92.3%). LRYGB demonstrated superior remission of type 2 diabetes (100% vs 66.7%, p = 0.038) and GERD (85.7% vs 40%, p = 0.015). Pregnancy-related complications, including gestational diabetes and hypertension, were minimal and resolved postpartum. No neonatal anomalies were reported. Cesarean section rates were high in both groups (63.1%–65.8%), likely reflecting cultural or provider preferences rather than surgical indication.</p> Conclusions <p>Both LSG and LRYGB are effective and safe in improving fertility, achieving significant weight loss, and supporting favorable pregnancy outcomes in morbidly obese women. LRYGB may be preferred for patients with metabolic comorbidities, especially type 2 diabetes and GERD. Metabolic Bariatric surgery should be considered early in reproductive planning for selected patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Female Fertility Outcome Following Bariatric Surgery: Five-Year Follow Up

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月9日

查看全文
  • Mohamed Shehata,
  • Wael Abosena,
  • Mohamed Elghazeery,
  • Ayman El-Dorf,
  • Mohammad Khirallah,
  • Ashraf El Attar

摘要

Background

To evaluate fertility, weight loss, improvement in obesity related comorbidities, and pregnancy outcomes over five years following metabolic bariatric surgery (laparoscopic sleeve gastrectomy [LSG] and laparoscopic Roux-en-Y gastric bypass [LRYGB]) in morbidly obese premenopausal women with infertility or planning pregnancy.

Methods

This retrospective cohort study included 79 adult females with morbid obesity who underwent LSG (n = 38) or LRYGB (n = 41). After 5 years of follow up: we evaluated percentage excess weight loss (%EWL), comorbidities improvement, postoperative complications or mortality, and fertility outcomes. Fertility outcomes were assessed in three subgroups: primary infertility (n = 21), secondary infertility (n = 8), and pre-marriage patients (n = 50).

Results

Both procedures achieved sustained weight loss (5-year %EWL: LSG 63.1 ± 1.5%, LRYGB 65.2 ± 8.1%; p = 0.16). Conception rates were high across all subgroups (primary infertility: LSG 80%, LRYGB 72.7%; secondary infertility: 100% both; pre-marriage: LSG 100%, LRYGB 92.3%). LRYGB demonstrated superior remission of type 2 diabetes (100% vs 66.7%, p = 0.038) and GERD (85.7% vs 40%, p = 0.015). Pregnancy-related complications, including gestational diabetes and hypertension, were minimal and resolved postpartum. No neonatal anomalies were reported. Cesarean section rates were high in both groups (63.1%–65.8%), likely reflecting cultural or provider preferences rather than surgical indication.

Conclusions

Both LSG and LRYGB are effective and safe in improving fertility, achieving significant weight loss, and supporting favorable pregnancy outcomes in morbidly obese women. LRYGB may be preferred for patients with metabolic comorbidities, especially type 2 diabetes and GERD. Metabolic Bariatric surgery should be considered early in reproductive planning for selected patients.